Welcome, Guest. Please login or register.
March 28, 2024, 08:35:10 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 772947
  • Total Topics: 66310
  • Online Today: 441
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 1
Guests: 343
Total: 344

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Washington Post Story on Monthly Injections to Control HIV  (Read 2652 times)

0 Members and 1 Guest are viewing this topic.

Offline Ptrk3

  • Global Moderator
  • Member
  • Posts: 2,792
Washington Post Story on Monthly Injections to Control HIV
« on: July 24, 2017, 04:56:14 pm »
The Washington Post is evidently covering 9th International AIDS Society conference in Paris this week.

Here's another story from the July 24, 2017, edition of the Washington Post, providing information on "monthly injections" that could replace daily medication.

From the story:

"On Monday, scientists reported an important advance in the development of a long-acting antiretroviral shot. According to an international study involving 309 patients, an injection that combines two drugs, cabotegravir and rilpivirine, appears to be as safe and effective at suppressing HIV as the daily oral regimen...

Writing in the Lancet, David Margolis of ViiV Healthcare, called it “the next revolution in HIV therapy...

The shots could revolutionize patient care in places like Africa, where it can be difficult for many people to get to a pharmacy regularly. But Mark A. Boyd, a professor at the University of Adelaide, wrote in a commentary piece accompanying the main article that there are trade-offs with both a pill and injection."

Link to story:

https://www.washingtonpost.com/news/to-your-health/wp/2017/07/24/monthly-shot-could-be-the-next-revolution-in-hiv-therapy-replacing-daily-pills/?utm_term=.710d4f3d0ce9

Link to "Lancet" text:

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31917-7/fulltext?elsca1=tlpr[thelancet.com]
HIV 101 - Basics
HIV 101
You can read more about Transmission and Risks here:
HIV Transmission and Risks
You can read more about Testing here:
HIV Testing
You can read more about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read more about HIV prevention here:
HIV prevention
You can read more about PEP and PrEP here
PEP and PrEP

Offline next2u

  • Member
  • Posts: 1,813
Re: Washington Post Story on Monthly Injections to Control HIV
« Reply #1 on: July 26, 2017, 10:38:22 am »
https://www.upi.com/Health_News/2017/07/24/Monthly-shot-as-safe-for-HIV-treatment-as-pills-Study/7631500927235/

MONDAY, July 24, 2017 -- Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

New research suggests that injectable, long-acting antiretroviral therapy for HIV is as safe and effective as oral medications. The injection -- given every four or eight weeks -- includes the drugs cabotegravir and rilpivirine.

"We have made considerable advances in the treatment of HIV over the last several decades," said study lead author Dr. David Margolis. "But for many patients living with HIV, it still remains a challenge to take daily oral medication, either because they are unable to or they choose not to. So it is important to find alternatives."

Margolis is medical director of ViiV Healthcare in Research Triangle Park, N.C., the developer of this new approach and the company that funded the trial.

Nearly 37 million people around the world are living with HIV. Advances in treatment have led to improved survival and quality of life. Current treatment, however, requires taking medications every day throughout life. Poor compliance can result in treatment failure or drug-resistant mutations of the virus. Long-acting, injectable drugs might be a more convenient way of managing HIV, the researchers said.

"This is the first study to use injections to treat HIV, and gives us a picture of the long-term durability of the treatment," Margolis said.

The report was published online July 24 in the journal The Lancet, to coincide with presentation of the results of the trial at the International AIDS Society meeting in Paris, France.

Dr. Mark Boyd is chair of medicine at Lyell McEwin Hospital at the University of Adelaide in Australia. He said, "This study shows us that we now have a new tool for managing HIV."

The more options available means that HIV management can be adapted to the specific requirements of each patient, he said.

"Whether this new injectable option will become a widespread popular form of HIV management or will cater to more of a niche market only time can tell," said Boyd, who co-authored an accompanying journal editorial.

The current study was a phase 2 trial. These trials are designed to show that a treatment is safe and effective. If a phase 2 trial is successful, then phase 3 trials are done to show that the treatment is effective in a large group of patients.

In the first 20 weeks of this trial, Margolis and his colleagues gave 309 patients with HIV -- who had never been on antiretroviral therapy -- daily oral doses of the antiretroviral drugs cabotegravir and abacavir-lamivudine.

This first step served to suppress the virus and test how well patients tolerated the drugs before moving on to injections.

In all, 286 patients were included in the balance of the study. The patients were randomly assigned to injections of cabotegravir plus rilpivirine every four or eight weeks, or to daily oral drugs.

After 32 weeks, HIV remained suppressed in 91 percent of those taking the drugs orally, in 94 percent of those receiving monthly injections and in 95 percent of patients receiving injections every two months, the researchers found.

At 96 weeks, viral suppression was maintained in 84 percent of patients taking oral medication, 87 percent of those receiving monthly injections and in 94 percent of those receiving injections every other month.

The most common side effects were pain at the site of the injection. Most reactions were mild or moderate and lasted an average of three days. Other side effects included symptoms of a common cold, diarrhea and headache, which were similar in all three groups.

Margolis said phase 3 trials are under way to test the effects of monthly injections in a larger number of patients. Based on these findings, the investigators will apply for approval from the U.S. Food and Drug Administration. Margolis hopes the injection therapy will be available in 2019.

Rowena Johnston, vice president and director of research at amfAR -- The Foundation for AIDS Research, said, "Anything that improves adherence, and therefore the treatment outcomes, of people living with HIV is totally a welcome advance."

Johnston thinks, however, that additional trials are needed to determine who would benefit most from this approach. Specifically, "Who are the people who want to use this kind of treatment?" she said.

This trial was done in the United States and Europe, Johnston pointed out, but since most people with HIV live in Africa and Asia, it would be important to see the acceptance of this treatment in those populations.

"Which patient would prefer an injection to an oral medication remains an open question," she said.

"The more options we have, the more people we can treat better, and that is the ultimate goal of HIV treatment. Different strokes for different folks," Johnston added.

More information
For more on HIV/AIDS, visit the U.S. Centers for Disease Control and Prevention.
midapr07 - seroconversion
sept07 - tested poz
oct07 cd4 1013; vl 13,900; cd4% 41
feb08 cd4  694;  vl 16,160; cd4% 50.1
may08 cd4 546; vl 91,480; cd4% 32
aug08 cd4 576; vl 48,190; cd4% 40.7
dec08 cd4 559; vl 63,020; cd4% 29.4
feb09 cd4 464; vl 11,000; cd4% 26
may09 cd4 544; vl 29,710; cd4% 27.2
oct09 cd4 ...; vl 23,350; cd4% 31.6
mar10 cd4 408; vl 59,050; cd4% 31.4
aug10 cd4 328; vl 80,000; cd4% 19.3 STARTED ATRIPLA
oct10 cd4 423; vl 410 ;); cd4% 30.2
jun11 cd4 439; vl <20 ;); cd4% 33.8 <-Undetectable!
mar12 cd4 695; vl ud; cd4% 38.6
jan13 cd4 738; vl ud; cd4% 36.8
aug13 cd4 930; vl ud; cd4% 44.3
jan14 cd4 813; vl ud; cd4% 42.8
may14 cd4 783; vl *; cd4%43.5
sept14 cd4 990; vl ud; cd4% *
jun15 cd4 1152; vl ud; cd4% *
july15 - STRIBILD
oct15 cd4 583; vl 146; cd4% 42
mar16 cd4 860; vl 20; 44

Offline Ptrk3

  • Global Moderator
  • Member
  • Posts: 2,792
Re: Washington Post Story on Monthly Injections to Control HIV
« Reply #2 on: July 26, 2017, 11:02:23 am »
The Washington Post also reported this story earlier this week and that info has been previously posted in this forum:

https://forums.poz.com/index.php?topic=66964.0
HIV 101 - Basics
HIV 101
You can read more about Transmission and Risks here:
HIV Transmission and Risks
You can read more about Testing here:
HIV Testing
You can read more about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read more about HIV prevention here:
HIV prevention
You can read more about PEP and PrEP here
PEP and PrEP

Offline Cosmicdancer

  • Member
  • Posts: 199
Re: Washington Post Story on Monthly Injections to Control HIV
« Reply #3 on: July 29, 2017, 12:23:11 am »
I wonder if a bi-monthly injection of a 2-drug combination would be significantly less expensive than 60 pills of a current 3-drug combination. 
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
2/2008 - 5/2015 - undetectable on Atripla
May, 2015 - UD, switched to Complera
September, 2015 - UD, 980 cd4, switched to Stribild (Complera interacted with acid reflux medication)
January, 2016 - Stribild, UD, 950 cd4
June, 2016 - UD, 929 cd4

Offline BKKKevin

  • Member
  • Posts: 159
Re: Washington Post Story on Monthly Injections to Control HIV
« Reply #4 on: July 29, 2017, 05:19:50 am »
The cost will depend on the patent laws of each country... that being said in the US it will be more expensive...

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.